Fig. 2

Proportion (95% CI) of patients achieving DAS28-4(ESR)-defined remission at month 3. Remission was defined as DAS28-4-(ESR) < 2.6. Data presented for the FAS; non responder imputation. Non-MTX csDMARD-IR (i.e., non-MTX csDMARD-IR but not bDMARD-IR) FAS: tofacitinib 5 mg BID, n = 184; tofacitinib 10 mg BID, n = 207; placebo, n = 50. MTX-IR (i.e., MTX-IR but not bDMARD-IR) FAS: tofacitinib 5 mg BID, n = 948; tofacitinib 10 mg BID, n = 969; placebo, n = 564. bDMARD-IR FAS: tofacitinib 5 mg BID, n = 229; tofacitinib 10 mg BID, n = 225; placebo, n = 175. bDMARD biologic disease-modifying antirheumatic drug, BID twice daily, CI confidence interval, csDMARD conventional synthetic disease-modifying antirheumatic drug, DAS28-4(ESR) Disease Activity Score in 28 joints derived from 4 measures, erythrocyte sedimentation rate, FAS full analysis set, IR inadequate response or intolerance, MTX methotrexate